7→6: Pest control quality compounder but 50x PE, analyst only 14.8% upside, below 200dma. Price $55.44 is above our $48-52 entry target zone. No identifiable catalyst near-term. Good business at fair-to-rich price = conv-6 by rubric (upside <15% at current price). Would rebuild to 7 if price corrects to entry zone.
Fair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
22.5%/yr
±4.2% · revenue growth to justify current price
FCF-Based Reverse DCF
20.4%/yr
±3.5% · FCF growth to justify current price
THE GAP
Market pricing margin expansion or capex normalization
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Eagle will generate this view by the next trading session (~7h).
Eagle will generate this view by the next trading session (~7h).
Falcon deep read confirms: 6.9% organic (residential ~5%, commercial ~8%, termite ~10%), 52.8% gross margin (+10bps), 20% adj op margin (+10bps), M FCF (+12.1%, 123% conversion). 75% recurring revenue...
FY2025: Revenue $3.761B (+11%), organic growth 6.9%, adj operating margin 20.0% (+10bps), adj EBITDA $855M (22.7%), FCF $650M (+12%). 26 acquisitions/buybacks including Saela. 2026 guidance: 7-8% orga...
ROL 2025 strong fundamentals: 6.9% organic growth, 20% adj operating margin, M FCF, 0.9x leverage. Q4 weather headwind noted. 2026 guide 7-8% organic growth. Solid execution on acquisition strategy.